



Comparative Study between Tadalafil versus Tamsulosin versus Halphabarol with Terpenes Mixture as a Medical Expulsive Therapy for Lower Ureteric Stones

Thesis

*Submitted for Partial Fulfilment of Master Degree in
Urology*

Presented by

Maysara Ebrahim Ali El-Menyawee
M.B.B.Ch

Under Supervision of

Prof. Dr. Khaled Abdel-Fattah Hassan Teama
Professor of Urology
Faculty of Medicine - Ain Shams University

Dr. Ashraf Yehia Khedr Abdel-salam
Lecturer of Urology
Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Khaled Abdel-Fattah Hassan Teama**, Professor of Urology, Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Ashraf Yehia Khedr Abdel-salam**, Lecturer of Urology, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I would like to express my hearty thanks to all **my Family and soul of my Father** for their support till this work was completed.*

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Maysara Ebrahim

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	vi
Introduction	1
Aim of the Study	7
Review of Literature	
📖 Anatomy of the Ureter	8
📖 Physiology of the Ureter	18
📖 Diagnosis of Ureteric Stones.....	23
📖 Treatment of Ureteric Stones	33
📖 Pharmacology of Terpenes Mixture (Rowatinex)	59
📖 Pharmacology of Halfa-Bar (Halphabarol).....	62
📖 Pharmacology of Alpha-1 Adrenergic Antagonists (Tamsulosin)	64
📖 Pharmacology of Phosphodiesterase-5 Inhibitors (Tadalafil).....	80
Patients and Methods	99
Results	105
Discussion	135
Summary	149
Conclusion.....	152
References	153
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Comparison between Intravenous urography and non-contrast computed tomography	31
Table (2):	Pharmacologic effects of terpenes	60
Table (3):	The results of 20 patients who were treated by tadalafil.	105
Table (4):	The results of 20 patients who were treated by tamsulosin	110
Table (5):	The results of 20 patients who were treated by Proximol with Rowatinex.....	115
Table (6):	Differences among the studied groups regarding age and gender	120
Table (7):	Differences among the studied groups regarding stone size, stone site and upper urinary tract	122
Table (8):	Differences among the studied groups regarding the stone expulsion rate and the stone expulsion time	125
Table (9):	Differences among the studied groups regarding the stone expulsion rate and the stone expulsion time with post-Hoc test	126
Table (10):	Differences among the studied groups regarding the number of patients who experienced renal colic episodes, the number of colic episodes and the number of injectable analgesic uses	128
Table (11):	Differences among the studied groups regarding the number of patients who experienced renal colic episodes, the number of colic episodes and the number of injectable analgesic uses with post-Hoc test	129

List of Tables (Cont...)

Table No.	Title	Page No.
Table (12):	Differences among the studied groups regarding the number of follow up ureteroscopic procedures	131
Table (13):	Differences among the studied groups regarding the number of follow up ureteroscopic procedures with post-Hoc test.....	132
Table (14):	Differences among the studied groups regarding side effects.....	133
Table (15):	Differences among the studied groups regarding the retrograde ejaculation and the increased erection with post-Hoc test.....	134

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Histology of the ureter.....	9
Fig. (2):	The lower ureters, urinary bladder, prostate and internal genitalia in male	11
Fig. (3):	Relations of the ovarian vessels and the uterine artery to the ureter during oophorectomy or hysterectomy	12
Fig. (4):	The ureter demonstrating sites of normal functional or anatomic narrowing at the ureteropelvic junction, the iliac vessels, and the ureterovesical junction	13
Fig. (5):	Arterial supply to the ureter	15
Fig. (6):	A JJ-stent is inserted to make sure urine can flow through the urinary tract.....	35
Fig. (7):	A percutaneous nephrostomy tube is used to drain urine directly from the kidney into the catheter bag.....	35
Fig. (8):	Rigid URS	55
Fig. (9):	Flexible URS and basket.....	56
Fig. (10):	Cymbopogan proximus herb.....	62
Fig. (11):	Mechanism of action of PDE5 inhibitors	84
Fig. (12):	Gender distribution in tadalafil group.	106
Fig. (13):	Stone site distribution in tadalafil group.....	106
Fig. (14):	Upper urinary tract distribution in tadalafil group.....	107
Fig. (15):	Stone expulsion rate in tadalafil group.	107
Fig. (16):	The number of patients who experienced renal colic episodes in tadalafil group.....	108

List of Figures (Cont...)

Fig. No.	Title	Page No.
Fig. (17):	The number of follow up ureteroscopic procedures in tadalafil group.....	108
Fig. (18):	Distribution of side effects in tadalafil group.	109
Fig. (19):	Gender distribution in tamsulosin group.....	111
Fig. (20):	Stone site distribution in tamsulosin group.....	111
Fig. (21):	Upper urinary tract distribution in tamsulosin group.	112
Fig. (22):	Stone expulsion rate in tamsulosin group.	112
Fig. (23):	The number of patients who experienced renal colic episodes in tamsulosin group.....	113
Fig. (24):	The number of follow up ureteroscopic procedures in tamsulosin group.	113
Fig. (25):	Distribution of side effects in tamsulosin group.....	114
Fig. (26):	Gender distribution in Proxamol with Rowatinex group.	116
Fig. (27):	Stone site distribution in Proxamol with Rowatinex group.	116
Fig. (28):	Upper urinary tract distribution in Proxamol with Rowatinex group.....	117
Fig. (29):	Stone expulsion rate in Proxamol with Rowatinex group.	117
Fig. (30):	The number of patients who experienced renal colic episodes in Proxamol with Rowatinex group.	118

List of Figures (Cont...)

Fig. No.	Title	Page No.
Fig. (31):	The number of follow up ureteroscopic procedures in Proximol with Rowatinex group.	118
Fig. (32):	Distribution of side effects in Proximol with Rowatinex group.	119
Fig. (33):	Difference among the studied groups regarding age	121
Fig. (34):	Difference among the studied groups regarding gender	121
Fig. (35):	Difference among the studied groups regarding stone size.....	123
Fig. (36):	Difference among the studied groups regarding stone site	123
Fig. (37):	Difference among the studied groups regarding upper urinary tract.....	124
Fig. (38):	Difference among the studied groups regarding stone expulsion rate	127
Fig. (39):	Difference among the studied groups regarding stone expulsion time	127
Fig. (40):	Difference among the studied groups regarding the number of patients who experienced renal colic episodes	130
Fig. (41):	Difference among the studied groups regarding the number of colic episodes and the number of injectable analgesic uses	130
Fig. (42):	Difference among the studied groups regarding the number of follow up ureteroscopic procedures.....	132
Fig. (43):	Differences among the studied groups regarding side effects	134

List of Abbreviations

Abb.	Full term
<i>AAG</i>	<i>Alpha-1-Acid Glycoprotein</i>
<i>Ach</i>	<i>Acetylcholine</i>
<i>ATP</i>	<i>Adenosine Triphosphate</i>
<i>AUC</i>	<i>Area under the Curve</i>
<i>BMI</i>	<i>Body Mass Index</i>
<i>BPH</i>	<i>Benign Prostatic Hyperplasia</i>
<i>Bpm</i>	<i>Beats per Minute</i>
<i>Ca²⁺</i>	<i>Calcium ions</i>
<i>cAMP</i>	<i>Cyclic Adenosine Monophosphate</i>
<i>cGMP</i>	<i>Cyclic Guanosine Monophosphate</i>
<i>cm</i>	<i>Centimeter</i>
<i>C_{max}</i>	<i>Maximum or Peak Concentration</i>
<i>CT</i>	<i>Computed Tomography</i>
<i>CYP</i>	<i>Cytochrome P450</i>
<i>CYP</i>	<i>Cytochrome P450</i>
<i>DAG</i>	<i>Diacylglycerol</i>
<i>DECT</i>	<i>Dual-Energy Computed Tomography</i>
<i>EAU</i>	<i>European Association of Urology</i>
<i>ED</i>	<i>Erectile Dysfunction</i>
<i>ESRD</i>	<i>End-Stage Renal Disease</i>
<i>ESWL</i>	<i>Extracorporeal Shockwave Lithotripsy</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>g/mol</i>	<i>Grams per Mole</i>
<i>Gc</i>	<i>Guanylate Cyclase or Guanylyl Cyclase</i>
<i>GMP</i>	<i>Guanosine Monophosphate</i>
<i>GPCR</i>	<i>G-Protein-Coupled Receptor</i>
<i>GTP</i>	<i>Guanosine Triphosphate</i>
<i>Ho: YAG</i>	<i>Laser Holmium: Yttrium-Aluminium-Garnet Laser</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>HS</i>	<i>Highly Significant</i>
<i>IFIS</i>	<i>Intraoperative Floppy Iris Syndrome</i>
<i>IP3</i>	<i>Inositol Trisphosphate</i>
<i>IVU</i>	<i>Intravenous Urography</i>
<i>K+</i>	<i>Potassium ions</i>
<i>kg/m²</i>	<i>Kilograms per Square Meter</i>
<i>KUB</i>	<i>Kidney, Ureter and Bladder Radiography</i>
<i>L2</i>	<i>2nd Lumbar Vertebra</i>
<i>L3</i>	<i>3rd Lumbar Vertebra</i>
<i>L4</i>	<i>4th Lumbar Vertebra</i>
<i>LUTS</i>	<i>Lower Urinary Tract Symptoms</i>
<i>M receptor</i>	<i>Muscarinic Receptor</i>
<i>MET</i>	<i>Medical Expulsive Therapy</i>
<i>mg</i>	<i>Milligram</i>
<i>mg/kg</i>	<i>Milligramper Kilogram</i>
<i>mL/min</i>	<i>Milliliter per Minute</i>
<i>mm</i>	<i>Millimeter</i>
<i>mmHg</i>	<i>Millimeters of Mercury</i>
<i>MRHD</i>	<i>Maximum Recommended Human Dose</i>
<i>mRNA</i>	<i>Messenger Ribonucleic Acid</i>
<i>MRU</i>	<i>Magnetic Resonance Urography</i>
<i>NAION</i>	<i>Non-Arteritic Anterior Ischemic Optic Neuropathy</i>
<i>NCCT</i>	<i>Non-Contrast Computed Tomography</i>
<i>NO</i>	<i>Nitric Oxide</i>
<i>NOS</i>	<i>Nitric Oxide Synthase</i>
<i>NS</i>	<i>Non Significant</i>
<i>NSAIDs</i>	<i>Non-Steroidal Anti-Inflammatory Drugs</i>
<i>PAH</i>	<i>Pulmonary Arterial Hypertension</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>PCN</i>	<i>Percutaneous Nephrostomy</i>
<i>PDE</i>	<i>Phosphodiesterase</i>
<i>PDE5</i>	<i>Phosphodiesterase Type 5</i>
<i>PKC</i>	<i>Protein Kinase C</i>
<i>PLC</i>	<i>Phospholipase C</i>
<i>PSA</i>	<i>Prostate Specific Antigen</i>
<i>PUJ</i>	<i>Pelviureteric Junction</i>
<i>RBCs</i>	<i>Red Blood Cells</i>
<i>RMP</i>	<i>Resting Membrane Potential</i>
<i>S</i>	<i>Significant</i>
<i>SFRs</i>	<i>Stone-Free Rates</i>
<i>SWL</i>	<i>Shockwave Lithotripsy</i>
<i>T_{1/2}</i>	<i>Terminal Plasma Half-Life</i>
<i>T_{max}</i>	<i>Time to Maximum or Peak Concentration</i>
<i>UPJ</i>	<i>Ureteropelvic Junction</i>
<i>URS</i>	<i>Ureteroscopy</i>
<i>US</i>	<i>Ultrasound</i>
<i>UTI</i>	<i>Urinary Tract Infection</i>
<i>V_d</i>	<i>Volume of Distribution</i>
<i>VUJ</i>	<i>Vesicoureteric Junction</i>
<i>WBCs</i>	<i>White Blood Cells</i>
α	<i>Alpha</i>
β	<i>Beta</i>

ABSTRACT

Background: urolithiasis is a health problem of worldwide importance. Urolithiasis is the third most common urological disease affecting the urinary tract after urinary tract infections and prostatic diseases. Ureteral stones account for 20% of urolithiasis, and 70% of ureteral stones are located in the lower third of the ureter. Ureteric stones have great bearing on the health as well as quality of life of the patient.

Aim of the Study: to compare the efficacy of tadalafil (a phosphodiesterase-5 inhibitor), tamsulosin (an alpha-1 blocker) and halphabarol (Proximol) with terpenes mixture (Rowatinex) as a medical expulsive therapy for lower ureteric stones.

Patients and Methods: this was a prospective randomized comparative study conducted on 60 patients between the ages of 20 and 40 years and complaining of unilateral single lower ureteric stone less than or equal to 8 mm presented through the outpatient clinics of Urology in Ain Shams University Hospitals and Damanhour Medical National Institute over a period of 10 months (from November 2017 to August 2018). The patients were randomly divided into 3 equal groups: Group A (20 patients were treated by tadalafil 5 mg once daily), Group B (20 patients were treated by tamsulosin 0.4 mg once daily) and Group C (20 patients were treated by Proximol with Rowatinex three times daily). Therapy was given for a maximum of 3 weeks. The patients were followed-up until stone passage or the end of the study period.

Results: the results of this study indicate that the stone expulsion rate was significantly higher in tadalafil group and tamsulosin group than Proximol with Rowatinex group (75% vs. 75% vs. 40%, P value = 0.030). Also, the mean stone expulsion time was significantly shorter in tadalafil group and tamsulosin group than Proximol with Rowatinex group (10.20 ± 3.91 days vs. 10.80 ± 3.64 days vs. 14.25 ± 3.28 days, P value = 0.046). The number of patients who experienced renal colic episodes, the number of colic episodes and the number of injectable analgesic uses were significantly lower in tadalafil group and tamsulosin group than Proximol with Rowatinex group (P value < 0.05). The number of follow up ureteroscopic procedures was significantly lower in tadalafil group and tamsulosin group than Proximol with Rowatinex group (25% vs. 25% vs. 60%, P value = 0.030). Also, the drugs are safe with mild few side effects.

Conclusion: PDE5 inhibitors (tadalafil) are equally efficacious to alpha-1 adrenergic antagonists (tamsulosin) in expulsion of lower ureteric stones less than or equal to 8 mm without any serious side effects. Comparing to Proximol with Rowatinex, both tadalafil and tamsulosin increase significantly the stone expulsion rate, decrease significantly the stone expulsion time and provide significant control of renal colicky pain, significantly less analgesic requirements and significantly lower follow up ureteroscopic procedures.

Keywords: Tadalafil - Tamsulosin - Halphabarol - Terpenes Mixture - Lower Ureteric Stones

INTRODUCTION

Urolithiasis, the formation of urinary stones, is a health problem of worldwide importance. Urolithiasis is the third most common urological disease affecting the urinary tract after urinary tract infections and prostatic diseases. The prevalence of urolithiasis varies between 2 and 20% throughout the world. The worldwide prevalence of the disease has been on the increase in the last three decades for both adult and children throughout the world (*Curhan, 2007*). Improved detection of stones, increasing lifespan, and dietary changes may be related to the increased prevalence of stone disease. There is a great deal of research suggests that the change of external factors take a significant place in the risk of occurrence of urolithiasis, even though genetic components also present a significant cause of urolithiasis (*Attanasio, 2011*).

Urinary stones are most prevalent between the ages of 20 and 40 years and are 3 times more common in men than women. Women excrete more citrate and less calcium than men, which partially explains the higher incidence of stone disease in men (*Manglaviti et al., 2011*). Some recent researches suggest that the epidemic factors of urolithiasis include: age, gender, obesity, hypertension, diabetes mellitus, gout, hyperparathyroidism, gastrointestinal diseases, diet, dehydration, immobilization, anatomic anomalies, medicines and disorder of calcium-phosphate metabolism (*Milicevic et al., 2014*).

Ureteral stones account for 20% of urolithiasis, and 70% of ureteral stones are located in the lower third of the ureter. Ureteric stones have great bearing on the health as well as quality of life of the patient (*Dellabella et al., 2005*). About 50% of patients who present with flank pain have a ureteric stone confirmed with imaging studies (*Smith et al., 1996*). Renal colic is one of the most painful conditions that may occur and it is often caused by stone in the distal portion of the ureter (*Segura et al., 1997*).

Spontaneous stone expulsion decreases with increasing stone size. It is estimated that 95% of ureteral stones smaller than 5 mm will pass spontaneously. This drops to 50% for stones greater than 5 mm. Stones greater than 6 mm have a lower rate of spontaneous passage. Duration of stone passage may be as long as 40 days (*Preminger et al., 2007*). The factors affecting spontaneous stone passage are the stone location, size, number, and structure, spasm of ureteral smooth muscles, mucosal oedema or inflammation, and ureteral anatomy. Of these, the location of the stone and its size are the most important factors (*Sur et al., 2015*). Therefore, the use of medical therapy is justifiable to reduce oedema, reduce spasm, and relax the smooth muscles for stone expulsion (*Seitz et al., 2009*).

Many factors are involved in the interaction between the ureter and stones, therefore it is useful to understand mechanisms involved in the contraction and relaxation of the ureter. These mechanisms would possibly lead to discovery of